Thyrolar
Name: Thyrolar
- Thyrolar uses
- Thyrolar 60 mg
- Thyrolar 60 mg tablet
- Thyrolar tablet
- Thyrolar side effects
- Thyrolar serious side effects
- Thyrolar drug
- Thyrolar effects of
- Thyrolar dosage
- Thyrolar action
- Thyrolar brand name
- Thyrolar dosage forms
- Thyrolar thyrolar tablet
- Thyrolar adverse effects
- Thyrolar weight loss
Notice:
Statement from Forest Laboratories Re: Availability of Thyrolar:
[Posted 5/18/2012] U.S. Pharmacopeia, an official public standards-setting authority for all prescription and over-the-counter medicines and other health care products manufactured or sold in the United States, has mandated new specifications for a component used in the manufacturing of Thyrolar. As a result, all strengths of Thyrolar are currently on long-term back order while Forest makes the modifications necessary to meet these new specifications.
Forest is working diligently to complete these modifications. In the meantime, patients should speak with their physician regarding appropriate treatment for their condition, and check for future updates on the availability of Thyrolar through the Forest product availability toll-free hotline at (866) 927-3260.
Dosing & Uses
Dosage Forms & Strengths
Each 60 mg tablet will replace approximately 60-65 mg (1 grain) of desicated thyroid
Liothyronine sodium (T3) is approximately 4 times as potent as levothyroxine (T4)
tablet, T3/T4
- Thyrolar 1/4 (15mg): 3.1/12.5mcg
- Thyrolar 1/2 (30mg): 6.25/25mcg
- Thyrolar 1 (60mg): 12.5/50mcg
- Thyrolar 2 (120mg): 25/100mcg
- Thyrolar 3 (180mg): 37.5/150mcg
Hypothyroidism
1 tab of Thyrolar 1/2 daily; follow with increments of 1 tab of Thyrolar 1/4 q2-3wk
Lower starting dose of 1 tab recommended in long-standing myxedema, especially if cardiovascular impairment suspected where extreme caution recommended
Maintenance: 1 tab Thyrolar 1 to 1 tab Thyrolar 2 per day; failure to respond to tab Thyrolar 3 may suggest lack of compliance or malabsorption
Adjust dose within the first 4 weeks of therapy after proper clinical laboratory evaluations where serum levels of T4 bound and free TSH are measured
Administer before breakfast
Dosage Forms & Strengths
Each 60 mg tablet will replace approximately 60-65 mg (1 grain) of desicated thyroid
Liothyronine sodium (T3) is approximately 4 times as potent as levothyroxine (T4)
tablet, T3/T4
- Thyrolar 1/4 (15mg): 3.1/12.5mcg
- Thyrolar 1/2 (30mg): 6.25/25mcg
- Thyrolar 1 (60mg): 12.5/50mcg
- Thyrolar 2 (120mg): 25/100mcg
- Thyrolar 3 (180mg): 37.5/150mcg
Congenital Hypothyroidism
0-6 months: 3.1/12.5 to 6.25/25 PO;
6-12 months: 6.25/25 to 9.35/37.5 PO;
1-5 years: 9.35/37.5-12.5/50 mcg PO;
6-12 years: 12.5/50-18.75/75 mcg PO;
>12 years: >18.75/75 mcg PO;
Administration: Before breakfast
Adverse Effects
Frequency Not Defined
Arrhythmias
Increased blood pressure
Chest pain
Palpitation
Anxiety
Headache
Urticaria
Changes in menstrual cycle
Insomnia
Hyperhydrosis pruritus
Tachycardia
Nervousness
Tremor
Cramps
Increased appetite
Weight loss
Diarrhea
Side effects
Precautions
Drug interactions
Clinical pharmacology
The steps in the synthesis of the thyroid hormones are controlled by thyrotropin (Thyroid Stimulating Hormone, TSH) secreted by the anterior pituitary. This hormone's secretion is in turn controlled by a feedback mechanism effected by the thyroid hormones themselves and by thyrotropin releasing hormone (TRH), a tripeptide of hypothalamic origin. Endogenous thyroid hormone secretion is suppressed when exogenous thyroid hormones are administered to euthyroid individuals in excess of the normal gland's secretion.
The mechanisms by which thyroid hormones exert their physiologic action are not well understood. These hormones enhance oxygen consumption by most tissues of the body, increase the basal metabolic rate, and the metabolism of carbohydrates, lipids, and proteins. Thus, they exert a profound influence on every organ system in the body and are of particular importance in the development of the central nervous system.
The normal thyroid gland contains approximately 200 mcg of levothyroxine (T4) per gram of gland, and 15 mcg of triiodothyronine (T3) per gram. The ratio of these two hormones in the circulation does not represent the ratio in the thyroid gland, since about 80 percent of peripheral triiodothyronine comes from mon-odeiodination of levothyroxine. Peripheral monodeiodination of levothyroxine at the 5 position (inner ring) also results in the formation of reverse triiodothyronine (T3), which is calorigenically inactive.
Triiodothyronine (T3) levels are low in the fetus and newborn, in old age, in chronic caloric deprivation, hepatic cirrhosis, renal failure, surgical stress, and chronic illnesses representing what has been called the "low triiodothyronine syndrome."
Pharmacokinetics
Animal studies have shown that T4 is only partially absorbed from the gastrointestinal tract. The degree of absorption is dependent on the vehicle used for its administration and by the character of the intestinal contents, the intestinal flora, including plasma protein, soluble dietary factors, all of which bind thyroid and thereby make it unavailable for diffusion. Only 41 percent is absorbed when given in a gelatin capsule as opposed to a 74 percent absorption when given with an albumin carrier.
Depending on other factors, absorption has varied from 48 to 79 percent of the administered dose. Fasting increases absorption. Malabsorption syndromes, as well as dietary factors (children's soybean formula, concomitant use of anionic exchange resins such as cholestyramine) cause excessive fecal loss. T3 is almost totally absorbed, 95 percent in 4 hours. The hormones contained in the natural preparations are absorbed in a manner similar to the synthetic hormones.
More than 99 percent of circulating hormones are bound to serum proteins, including thyroid-binding globulin (TBg), thyroid-binding prealbumin (TBPA), and albumin (TBa), whose capacities and affinities vary for the hormones. The higher affinity of levothyroxine (T4) for both TBg and TBPA as compared to triiodothyronine (T3) partially explains the higher serum levels and longer half-life of the former hormone. Both protein-bound hormones exist in reverse equilibrium with minute amounts of free hormone, the latter accounting for the metabolic activity.
Deiodination of levothyroxine (T4) occurs at a number of sites, including liver, kidney, and other tissues. The conjugated hormone, in the form of glucuronide or sulfate, is found in the bile and gut where it may complete an enterohepatic circulation. Eighty-five percent of levothyroxine (T4) metabolized daily is deiodinated.
Commonly used brand name(s)
In the U.S.
- Euthroid
- Thyrolar
Available Dosage Forms:
- Tablet
Therapeutic Class: Thyroid Supplement
What are some things I need to know or do while I take Thyrolar?
- Tell all of your health care providers that you take this medicine. This includes your doctors, nurses, pharmacists, and dentists.
- Do not run out of Thyrolar.
- If you have high blood sugar (diabetes), you will need to watch your blood sugar closely.
- Have blood work checked as you have been told by the doctor. Talk with the doctor.
- If you are taking warfarin, talk with your doctor. You may need to have your blood work checked more closely while you are taking it with this medicine.
- If you are 65 or older, use Thyrolar with care. You could have more side effects.
- Use with care in children. Talk with the doctor.
- Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this medicine while you are pregnant.
- Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.
How supplied
Thyrolar Tablets (Liotrix Tablets, USP) are available in five potencies coded as follows:
Composition | ||||
Name | (T3/T4 per tablet) | Color | Armacode® | NDC |
Thyrolar-1/4 | 3.1 mcg/ 12.5 mcg | Violet/White | YC | 0456-0040-01 |
Thyrolar-1/2 | 6.25 mcg/ 25 mcg | Peach/White | YD | 0456-0045-01 |
Thyrolar-1 | 12.5 mcg/ 50 mcg | Pink/White | YE | 0456-0050-01 |
Thyrolar-2 | 25 mcg/ 100 mcg | Green/White | YF | 0456-0055-01 |
Thyrolar-3 | 37.5 mcg/ 150 mcg | Yellow/White | YH | 0456-0060-01 |
Supplied in bottles of 100, two-layered compressed tablets.
Tablets should be stored at cold temperature, between 36˚F and 46˚F (2˚C and 8˚C) in a tight, light-resistant container.
Note: (T3 liothyronine sodium is approximately four times as potent as T4 thyroxine on a microgram for microgram basis.)
FOREST PHARMACEUTICALS, INC.
A Subsidiary of Forest Laboratories, Inc.
St. Louis, MO 63045
Rev. January 2010
RMC #1436
© 2010 Forest Laboratories, Inc.
Introduction
Synthetic thyroid agent; combination preparation containing tetraiodothyronine (levothyroxine, T4) sodium and triiodothyronine (liothyronine, T3) sodium.a b c d j
Cautions for Thyrolar
Contraindications
-
Untreated thyrotoxicosis.b j
-
AMI uncomplicated by hypothyroidism.j
-
Uncorrected adrenal insufficiency.b j
-
Known hypersensitivity to any ingredient in the formulation.b j (See Sensitivity Reactions under Cautions.)
Warnings/Precautions
Warnings
Unlabeled UsesShould not be used for the treatment of obesity or for weight loss either alone or with other therapeutic agents.b j k r In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction.b j r Larger doses may produce serious or life-threatening toxicity, particularly when given in conjunction with sympathomimetic amines (e.g., anorectic agents).b j r
Should not be used in the treatment of male or female infertility unless this condition is associated with hypothyroidism.b j k r
Sensitivity Reactions
Hypersensitivity to thyroid hormone is not known to occur.b However, hypersensitivity reactions to inactive ingredients of thyroid hormone products have been reported and include urticaria, pruritus, rash, flushing, angioedema, abdominal pain, nausea, vomiting, diarrhea, fever, arthralgia, serum sickness, and wheezing.j
Major Toxicities
Effects on Bone Mineral DensityIncreased markers of bone turnover.d
General Precautions
Therapy MonitoringThyroid agents have a narrow therapeutic index.j Avoid undertreatment or overtreatment, which may result in adverse effects on growth and development in pediatric patients, cardiovascular function, bone metabolism, reproductive function, cognitive function, emotional state, GI function, and glucose and lipid metabolism.j
Periodically perform appropriate laboratory tests (e.g., serum TSH, total or free T4, total T3) and clinical evaluations to monitor adequacy of therapy.a b c j
Preexisting Cardiovascular DiseaseUse with extreme caution.b j (See Patients with Cardiovascular Disease under Dosage and Administration.) Patients with CHD should be monitored closely during surgical procedures due to increased risk of arrhythmias.j
Associated Endocrine DisordersHypopituitarism, adrenal insufficiency, and other endocrine disorders such as diabetes mellitus and diabetes insipidus are characterized by signs and symptoms which may be diminished in severity or obscured by hypothyroidism.j Thyroid agents may aggravate the intensity of previously obscured symptoms in patients with endocrine disorders, and appropriate adjustment of therapy for these concomitant disorders may be required.b j
In patients with secondary or tertiary hypothyroidism, consider possibility of additional hypothalamic/pituitary hormone deficiencies and treat if diagnosed.q
Chronic autoimmune thyroiditis may occur in association with other autoimmune disorders (e.g., adrenal insufficiency, pernicious anemia, type 1 diabetes mellitus.)e f
Patients with concomitant adrenal insufficiency should be treated with replacement corticosteroids prior to initiation of thyroid agents.j Failure to do so may precipitate an acute adrenal crisis due to increased metabolic clearance of corticosteroids when the thyroid agent is initiated.j
Patients with diabetes mellitus may require increased dosages of antidiabetic agents when treated with thyroid agents.b j
Specific Populations
PregnancyCategory A.b
During pregnancy, serum free T4 levels may decrease and serum TSH levels increase to values outside the normal range.d q Elevations in serum TSH may occur at 4 weeks’ gestation;q monitor TSH levels during each trimester (or every 6 weeks) and adjust liotrix dosage accordingly.d e k Reduce dosage to pre-pregnancy level immediately after delivery, since postpartum TSH concentrations are similar to preconception levels; measure serum TSH concentrations 6–8 weeks postpartum.q
LactationAlthough thyroid hormones are distributed minimally into human milk, exercise caution when administering to a nursing woman.b However, adequate replacement dosages generally are needed to maintain normal lactation.o q
Pediatric UseThe goal of treatment in pediatric patients with hypothyroidism is to achieve and maintain normal intellectual and physical growth and development.b j Initiate therapy immediately upon diagnosis.b j Maintain therapy for life, unless transient hypothyroidism is suspected.b j
Neonates with suspected hypothyroidism should receive thyroid agent therapy pending results of confirmative tests.j If a positive diagnosis cannot be made on the basis of laboratory findings but there is a strong clinical suspicion of congenital hypothyroidism, initiate replacement therapy to achieve euthyroidism until the child is 1–2 years of age.j During the first 2 weeks of therapy, closely monitor infants for cardiac overload, arrhythmias, and aspiration resulting from avid suckling.j Evaluate infant’s clinical response to therapy about 6 weeks after initiation of thyroid agent therapy and at least at 6 and 12 months of age and yearly thereafter.j
When transient hypothyroidism is suspected, temporarily discontinue therapy for 2–8 weeks to reassess the condition when the child is >3 years of age.b j m If the diagnosis of permanent hypothyroidism is confirmed, reinstitute full replacement therapy.j However, if serum concentrations of free T4 and TSH are normal, discontinue thyroid agent therapy and monitor carefully;b j repeat thyroid function tests if manifestations of hypothyroidism develop.j
In pediatric patients with transient severe hypothyroidism, reduce replacement dose by half for 30 days to reassess condition.m If, after 30 days, serum TSH >20 mU/L, consider the hypothyroidism permanent and reinstitute full replacement therapy.m However, if serum TSH has not increased, temporarily discontinue thyroid agent therapy for another 30 days, then repeat serum free T4 and TSH measurements.m Reinstitute or discontinue replacement therapy based on laboratory findings.m
Monitor patients closely to avoid undertreatment or overtreatment.j Undertreatment may result in poor school performance (due to impaired concentration and slowed mentation) and reduced adult height.j Overtreatment may result in craniosynostosis in infants and accelerate aging of bones, resulting in premature epiphyseal closure and compromised adult stature.j m
Treated children may manifest a period of catch-up growth, which may be adequate in some cases to achieve normal adult height.j In children with severe or long-standing hypothyroidism, catch-up growth may not be adequate to achieve normal adult height.j
Pseudotumor cerebri and slipped capital femoral epiphysis have been reported in children receiving thyroid agents.j
Geriatric UseBecause of the increased risk of cardiovascular disease among geriatric patients, liotrix therapy should not be initiated at the full replacement dose.b j k (See Geriatric Patients under Dosage and Administration.)
Common Adverse Effects
Adverse reactions result from overdosage and resemble manifestations of hyperthyroidism,a b j including fatigue,b j weight loss,j increased appetite,j heat intolerance,j fever,j excessive sweating,b j headache,b j hyperactivity,j nervousness,j anxiety,b j irritability,j emotional lability,j insomnia,b j tremor,b j muscle weakness,j palpitations,b j tachycardia,j arrhythmias,b j increased heart rate and BP,b j heart failure,j angina,j AMI,j cardiac arrest,j diarrhea,j vomiting,j abdominal cramps,j elevations in liver function test results,j hair loss,b j flushing,j decreased bone mineral density,j menstrual irregularities,j and impaired fertility.j
Stability
Storage
Oral
TabletsTight, light-resistant containers at 2–8°C.a b
Liotrix Breastfeeding Warnings
Caution is recommended.
Excreted into human milk: Yes
Comments:
-This drug is a mixture of levothyroxine (T4) and liothyronine (T3) which are normal components of human milk.
-Limited data on exogenous replacement doses of T4 show no adverse effects on nursing infants.
-Dose requirements may be increased in the postpartum period compared to pre-pregnancy requirements in women with Hashimoto's thyroiditis.